We are live on ! Find out more

Rigel Pharmaceuticals

RIGL

Market cap $961M

51.45 USD

+0.71

1.4%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

49.74

-1.71

3.32%

1 day

1.4%

5 days

6.13%

1 month

5.24%

3 months

31.69%

6 months

76.08%

Year to date

23%

1 year

75%

5 years

53.13%

10 years

97.88%

About: Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.

Employees: 174

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 25%

Neutral 58.3%

Negative 16.7%

Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2026 financial results after market close on Thursday, November 5, 2026.

Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results

Rigel Pharmaceuticals: Turning Big Pharma's Castoffs Into A Growth Engine

Rigel Pharmaceuticals is evolving into a multi-product oncology platform, leveraging Big Pharma castoffs to drive growth beyond its ITP legacy. VEPPANU's U.S. launch targets a $1B ESR1-mutated breast cancer market, with early metrics excluded from current guidance and valuation multiples. RIGL trades at a 25–39% discount to sector medians on forward P/E and EV/Sales, while base business demonstrates robust double-digit sales growth and high gross margins.

Rigel Pharmaceuticals: Turning Big Pharma's Castoffs Into A Growth Engine

Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026

Pooled ARROW and TAPISTRY analysis demonstrated a 53% overall response rate in patients with RET fusion-positive solid tumors Additional analyses highlight first-line clinical outcomes and patient-reported quality of life in RET fusion-positive NSCLC and efficacy and safety in RET fusion-positive thyroid cancer SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced analysis of the pooled efficacy and safety data from two clinical trials of GAVRETO® (pralsetinib), ARROW (NCT03037385) and TAPISTRY (NCT04589845), in patients with rearranged during transfection (RET) fusion-positive solid tumors will be presented in a rapid oral session at the European Society For Medical Oncology (ESMO) Congress 2026 on Sunday, October 25, 2026.

Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Oct. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Rigel to Participate in Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will participate in the following investor conferences in September: Citi's 2026 Biopharma Back to School Conference in New York, NY Rigel will participate in one-on-one meetings on Wednesday, September 9.

Rigel to Participate in Upcoming September Investor Conferences

Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

VEPPANU is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, ESR1-mutated mBC SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced VEPPANUTM (vepdegestrant) is now available by prescription in the United States for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer (mBC), as detected by a U.S. Food and Drug Administration (FDA)-authorized test, with disease progression following at least one line of endocrine therapy.

Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead

Rigel Pharmaceuticals in-licensed Veppanu, a drug for the treatment of certain breast cancer patients, targeting a $1B market, with revenues expected as early as Q3'26. Q2'26 saw strong sales growth from Tavalisse and Rezlidhia, offsetting Gavreto's middling performance. RIGL guides $285M–$295M 2026 revenues, excluding Veppanu upside. Upcoming R289 phase 1b data for LR-MDS and future readouts from Veppanu and Rezlidhia trials provide additional growth catalysts.

Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead

Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade)

Rigel's Q2 beat big ($78.7M revenue, $0.88 EPS), driven by TAVALISSE, but GAVRETO's year-over-year decline is concerning. Guidance raise came from contract revenue, not accelerating core product sales; net product sales guidance unchanged. VEPPANU is strategically sound but adds only incremental value after upfront payments, milestones, and high royalties.

Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade)

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2026 Earnings Call Transcript

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2026 Earnings Call Transcript

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2026 Earnings Call Transcript

Rigel Pharmaceuticals Q2 Earnings Call Highlights

Rigel Pharmaceuticals NASDAQ: RIGL reported second-quarter 2026 total revenue of $78.7 million and net income of $17.3 million, while outlining plans to launch newly licensed breast cancer therapy VEPPANU in mid-August.

Rigel Pharmaceuticals Q2 Earnings Call Highlights

See News Rankings

Price charts implemented using Lightweight Charts™